The epidermal growth factor receptor (EGFR) is a well-established target for anticancer therapy because it is expressed or overexpressed in a variety of tumours, including non-small cell lung cancer (NSCLC) (Rusch et al, 1993). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.